BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 17, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 13, 2005
View Archived Issues
Cephalon's Parkinson's Study Stopped; No Benefit Showed
Cephalon Inc. called a halt to a late-stage study of a partnered Parkinson's disease drug, CEP-1347, as interim results revealed a lack of clinical benefit. (BioWorld Today)
Read More
CuraGen Partner Signs CRADA; Subsidiary 454 Enters $62M Deal
Read More
Tranzyme's Story: Early Stage Firm Brings In $32M Financing
Read More
Spherics Gets $26M To Push Bioadhesive Drug Delivery
Read More
Other News To Note
Read More